Can CereVasc’s $85m raise move hydrocephalus treatment beyond traditional shunt surgery?
CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.
Resolve M Therapeutics exits stealth with Johnson & Johnson Innovation support to pursue MS1-driven immune resolution
Resolve M exits stealth with a bold MS1-based approach to inflammation. Learn how its pro-resolution platform could reshape autoimmune drug development.